Introduction {#s1}
============

Melanoma brain metastasis (MBM) is a known characteristic for poor prognosis. The median overall survival (mOS) in the era of chemotherapy was 4 months and decreased to 2 months in patients with elevated lactate dehydrogenase (LDH).[@R1] The response of MBM to chemotherapy was approximately 5%. This applies to both, drugs that cross the blood-brain barrier, such as temozolomide and fotemustine, and to drugs that do not cross the blood-brain barrier, such as dacarbazine.[@R3] The American Joint Committee on Cancer has acknowledged the negative impact of brain metastasis on the prognosis of patients with melanoma in its latest eighth edition staging system by defining this subgroup as M1d.[@R5]

With the introduction of targeted treatment (BRAF/MEK inhibitors) and immune checkpoint inhibitors, the prognosis of metastatic melanoma has drastically improved.[@R6] In contrast to ample data on the efficacy of novel therapies in stage IV melanoma without MBM, there are only a few small studies on the efficacy of these drugs in patients with cerebral disease. This lack of information is mainly due to the fact that large phase II/III multicenter studies systematically excluded patients with MBM, particularly if symptomatic or previously treated with local therapy, such as stereotactic radiosurgery and surgery (STR/surgery). The first studies investigating targeted therapy and immune checkpoint inhibitors in patients with MBM showed that these therapies were also very effective intracranially.[@R9] Currently available data suggest that PD-1-based immunotherapy and particularly combined immunotherapy with nivolumab and ipilimumab (NIVO+IPI) might be more effective than BRAF/MEK inhibitors.[@R8] In two retrospective studies with patients with MBM, the authors reported that patients receiving immunotherapy had a mOS between 13 and 14.8 months (95% CI: 8.1 to 17.8 and 9.9 to 19.7, respectively), while in those receiving targeted therapy the mOS was only 7 and 10 months (95% CI: 3.8 to 10.2 and 7.8 to 11.7, respectively).[@R14] This difference was also present when these systemic therapies were given in combination with stereotactic radiosurgery, favoring the combination with immunotherapy, which resulted in a mOS between 21--25 months (95% CI: 12.9 to 29.1 and 14.6 to 35.4, respectively) and 12.9--14 months with targeted therapy (95% CI: 12.9 to 29.1 and 9.1 to 16.7, respectively).

Our study provides real-world outcome data from 23 German skin cancer centers, retrospectively assessing the activity of NIVO+IPI alone or in combination with local therapies regardless of treatment line in patients with asymptomatic and symptomatic MBM.

We addressed the following questions: (a) Which prognostic factors for OS can be identified in patients with MBM treated with combined immunotherapy? (b) Does local therapy (STR/surgery) improves survival in patients with MBM treated with NIVO+IPI? (c) Are STR/surgery more effective when given before or after combined immunotherapy? (d) Is there a difference in terms of survival when combined immunotherapy is given as a first-line treatment for MBM or later in the course of the disease? (e) In patients with BRAF V600-mutated melanoma, which first-line systemic therapy for MBM translates into better OS: first-line immunotherapy or first-line targeted therapy? (f) Is there a difference in terms of OS when patients with symptomatic and asymptomatic MBM receive NIVO+IPI? Since a total of 380 patients were included, we were able to perform subgroup analyses with reasonable statistical power.

Methods {#s2}
=======

Patients' characteristics and treatments {#s2-1}
----------------------------------------

We used pseudo-anonymized forms to document retrospective data from patients with MBM treated with NIVO+IPI between April 2015 and October 2018. All participating centers received the mentioned pseudo-anonymized forms including the prespecified information to be collected. Data were extracted from patients' medical records in 23 German skin cancer centers either by medical doctors or by clinical research documentation professionals, depending on the site. Patients were included regardless of previous local or systemic therapies, provided that they received combined immunotherapy for treating MBM.

Multiple MBM were irradiated by whole brain irradiation with opposite lateral field in mask technique. Stereotactic radiosurgery was used to irradiate small brain metastasis. Neuroimaging consisted of a stereotactic three-dimensional T1-weighted postcontrast Magnetic Ressonance Imaging (MRI) acquisition und an planning CT scan. Selection of dosimetry parameters (maximum dose, marginal isodose and number of isocenters) was made according to size, shape, localization and relationship for brain metastasis to critical structures. Target localization was referenced to a coordination system and target position was tracked during treatment. The data cut-off date was October 31, 2018.

Statistical Analysis {#s2-2}
--------------------

We performed univariate and multivariate Cox regression analysis to evaluate the impact of baseline patient and disease characteristics on OS. Cox multivariate analysis included the following factors: sex, BRAF mutation status, number of MBM, Eastern Cooperative Oncology Group performance status (ECOG-PS) as categorical variables and age, LDH level and protein S100B level as both categorical and numerical variables. The use of corticosteroids at the start of combined immunotherapy was also documented. As these data are rather complex regarding dosage and duration of each individual treatment, they will be analyzed in a separate investigation.

OS and follow-up (FU) time were calculated considering the date of MBM diagnosis and last patient contact or death. Kaplan-Meier estimates were used for the calculation of OS. Differences between groups were assessed using the log-rank test. Patients were grouped considering the timing of combined immunotherapy (first-line or not first-line) for treatment of MBM and according to BRAF mutation status (BRAFV600 mutant or BRAF wild type). Pretreatment protein S100B and LDH values were assigned categorical variables (normal, elevated and 2-fold or 10-fold elevated), according to the institutional upper limit of normal. Patients with missing values were excluded from the respective analysis. Further subgroups considering the number of MBM, presence of neurological symptoms and ECOG-PS were defined. To investigate the effect of local therapies on OS, data from patients receiving STR/surgery were compared with data from patients not receiving local therapies. Timing of local therapy and its effect on OS were analyzed by defining two groups: STR/surgery before start of NIVO+IPI treatment or STR/surgery at a later time point. Patients treated with whole brain radiotherapy (WBRT) were evaluated separately. Results are reported as two-sided p values with 95% CIs. Statistical significance was set at p\<0.05.

Results {#s3}
=======

Patients characteristics {#s3-1}
------------------------

A total of 380 patients with MBM and NIVO+IPI treatment were included in the analysis ([table 1](#T1){ref-type="table"}, [online supplementary figure S1](#SP1){ref-type="supplementary-material"}). Thirty-seven per cent of the patients were females and median age at the time of MBM diagnosis was 58 years (IQR 49--68). The majority of melanomas (63.7%) carried a BRAFV600 mutation.
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###### 

Patients characteristics of the whole collective (n=380) considering combined immunotherapy at first line or not at first line

  Baseline characteristics                Total        CombiIT first line   CombiIT not first line   P value\*
  --------------------------------------- ------------ -------------------- ------------------------ -------------------
  Sex                                                                                                
   Male                                   240 (63.2)   165 (66)             75 (57.7)                0.111
   Female                                 140 (36.8)   85 (44)              55 (42.3)                
  Age (years) at the time of CombiIT                                                                 
   \<54                                   153 (40.3)   90 (36)              63 (48.5)                **0.024**
   54--64                                 105 (27.6)   69 (27.6)            36 (27.7)                
   \>64                                   122 (32.1)   91 (36.4)            31 (23.8)                
  BRAF status                                                                                        
   BRAF wild type                         138 (36.3)   112 (44.8)           26 (20)                  **\<** **0.0001**
   BRAF mutant                            242 (63.7)   138 (55.2)           104 (80)                 
  LDH level†                                                                                         
   Normal                                 189 (51.4)   131 (54.1)           58 (46.0)                0.223
   Elevated                               133 (36.1)   85 (35.1)            48 (38.1)                
   2×\>ULN                                46 (12.5)    26 (10.8)            20 (15.9)                
  S100B level†                                                                                       
   Normal                                 109 (32.8)   69 (31.2)            40 (36.4)                0.597
   Elevated                               156 (47)     106 (47.7)           50 (45.4)                
   10×\>ULN                               67 (20.2)    47 (21.1)            20 (18.2)                
  Number of MBM at the time of CombiIT†                                                              
   1--3                                   167 (46.8)   127 (53.6)           40 (33.3)                **\<** **0.0001**
   \>3                                    190 (53.2)   110 (46.4)           80 (66.7)                
  ECOG-PS†                                                                                           
   0                                      249 (66.4)   168 (67.7)           81 (63.8)                0.741
   1                                      87 (23.2)    55 (22.2)            32 (25.2)                
   \>1                                    39 (10.4)    25 (10.1)            14 (11)                  
  Presence of symptoms†                                                                              
   Yes                                    60 (31)      44 (32.1)            16 (28.6)                0.629
   No                                     133 (69)     93 (67.9)            40 (71.4)                
  Local therapy                                                                                      
   STR/surgery‡                           220 (57.9)   135 (54)             85 (65.4)                **0.011**
   No local therapy                       90 (23.7)    71 (28.4)            19 (14.6)                
   WBRT                                   70 (18.4)    44 (17.6)            26 (20)                  

Bold values indicate statistically significant results.

\*Pearson's χ^2^ test.

†Denotes variables for which the missing/unknown values were excluded from the analysis.

‡Ten patients (4.5%) received only surgery. Four patients receiving STR/surgery before combined immunotherapy and two patients receiving STR/surgery after combined immunotherapy were treated with the two techniques within an interval of 2 weeks.

CombiIT, nivolumab plus ipilimumab; ECOG-PS, Eastern Cooperative Oncology Group performance status; MBM, melanoma brain metastases; n, number of patients in each subgroup; STR, stereotactic radiosurgery; ULN, upper level normal; WBRT, whole brain radiotherapy.

In the univariate Cox regression analysis ([table 2](#T2){ref-type="table"}), we found the following significant prognostic factors for OS: LDH level, favoring patients with normal LDH (p\<0.0001), number of MBM (p=0.001) favoring patients with 1--3 MBM and ECOG-PS (p=0.001) favoring patients with ECOG-PS=0. No significant OS difference was observed for baseline S100B level (p=0.099), BRAFV600 mutation status (p=0.962), age groups (p=0.616), sex (p=0.682) and presence of symptomatic MBM (p=0.078). Multivariate Cox regression analysis using categorical variables ([table 2](#T2){ref-type="table"}) showed that the number of MBM (p=0.008) and ECOG-PS (p=0.006) were independent prognostic factors for OS. In the multivariate Cox regression analysis using numerical variables for age, serum LDH and protein S100B ([online supplementary table S4](#SP1){ref-type="supplementary-material"}), the following prognostic factors were found to be an independently associated with OS: LDH (p=0.001), protein S100B (p=0.001), number of MBM (p=0.017) and ECOG-PS (p=0.041).

###### 

Impact of baseline patient and disease characteristics on overall survival: univariate and multivariate Cox regression analysis

  -----------------------------------------------------------------------------------------------------------------------------------
                                           Total\       Univariate analysis   P value             Multivariate analysis   P value
                                           N (%)                                                                          
  ---------------------------------------- ------------ --------------------- ------------------- ----------------------- -----------
  Gender                                                                                                                  

   Male                                    240 (63.2)   1                                         1                       0.855

   Female                                  140 (36.8)   0.94 (0.69 to 1.27)   0.682               1.35 (0.70 to 1.50)     

  Age (years) at the time of CombiIT                                                                                      

   \<54                                    153 (40.3)   1                     0.616               1                       0.689

   54--64                                  105 (27.6)   1.13 (0.78 to 1.62)                       1.17 (0.75 to 1.81)     0.491

   \>64                                    122 (32.1)   1.19 (0.83 to 1.70)                       1.20 (0.76 to 1.90)     0.428

  BRAF status                                                                                                             

   BRAF wild type                          138 (36.3)   1                     0.962               1                       

   BRAF mutant                             242 (63.7)   0.99 (0.72 to 1.37)                       1.13 (0.76 to 1.67)     0.548

  LDH level\*                                                                                                             

   Normal                                  189 (51.4)   1                     **\<** **0.0001**   1                       0.069

   Elevated                                133 (36.1)   1.24 (0.88 to 1.74)                       1.05 (0.69 to 1.59)     0.831

   2×\>ULN                                 46 (12.5)    2.53 (1.67 to 3.83)                       1.80 (1.05 to 3.09)     **0.031**

  S100B level\*                                                                                                           

   Normal                                  109 (32.8)   1                     0.099               1                       0.325

   Elevated                                156 (47)     1.35 (0.92 to 2.00)                       1.39 (0.90 to 2.11)     0.135

   10×\>ULN                                67 (20.2)    1.61 (1.02 to 2.54)                       1.30 (0.76 to 2.24)     0.341

  Number of MBM at the time of CombiIT\*                                                                                  

   1--3                                    167 (46.8)   1                     **0.001**           1                       **0.008**

   \>3                                     190 (53.2)   1.74 (1.26 to 2.40)                       1.67 (1.14 to 2.44)     

  ECOG-PS\*                                                                                                               

   0                                       249 (66.4)   1                     **0.001**           1                       **0.006**

   1                                       87 (23.2)    1.3 (0.91 to 1.87)                        1.31 (0.87 to 1.99)     0.188

   \>1                                     39 (10.4)    2.58 (1.66 to 4.00)                       2.42 (1.39 to 4.20)     **0.002**

  Presence of symptomatic MBM\*                                                                                           

   No                                      133 (69)     1                                                                 

   Yes                                     60 (31)      1.46 (0.96 to 2.23)   0.078               N/A                     
  -----------------------------------------------------------------------------------------------------------------------------------

Bold values indicate statistically significant results (p\<0.05).

\*Denotes variables for which the missing/unknown values were excluded from the analysis.

CombiIT, nivolumab plus ipilimumab; ECOG-PS, Eastern Cooperative Oncology Group performance status; MBM, melanoma brain metastases; N, number of patients in each subgroup; N/A, not performed for this factor, since information was available to only 50% of the patients; ULN, upper level normal.

Overall survival analysis considering systemic and local therapy {#s3-2}
----------------------------------------------------------------

The mOS for the whole cohort was 19 months (95% CI: 15.9 to 22.0) and the median FU time was 18 months (IQR 9--28 months). The 1-year, 2-year and 3-year OS rates were 69%, 41.1% and 30.1%, respectively ([table 3](#T3){ref-type="table"}; [figure 1A](#F1){ref-type="fig"}; 95% CI: 63.5 to 74.5; 34.9 to 47.9 and 22.2 to 37.9, respectively).

![Kaplan-Meier curves for overall survival (A) and considering the different factors: (B) BRAF status; (C) LDH level; (D) number of melanoma brain metastases (MBM) at the time of therapy with nivolumab+ipilimumab; (E) protein S100B level; (F) best intracranial response. CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease.](jitc-2019-000333f01){#F1}

###### 

Median OS and 1-year, 2-year and 3-year OS rates

  ---------------------------------------------------------------------------------------------------------------------------
                                    mOS (months) (95% CI)   1-year OS\            2-year OS\            3-year OS\
                                                            (%; 95% CI)           (%; 95% CI)           (%; 95% CI)
  --------------------------------- ----------------------- --------------------- --------------------- ---------------------
  All patients                      19 (15.9 to 22.0)       69 (63.5 to 74.5)     41.1 (34.9 to 47.9)   30.1 (22.2 to 37.9)

  Number of MBM                                                                                         

   1--3                             29 (16.9 to 41.4)       71.2 (63.6 to 78.8)   57.0 (46.8 to 67.2)   42.3 (28.6 to 56.0)

   \>3                              14 (10.2 to 17.9)       52.1 (44.3 to 59.9)   32.2 (23.9 to 40.4)   22.7 (13.5 to 31.9)

  BRAF status                                                                                           

   BRAF wild type                   19 (14.9 to 23.0)       61.3 (51.9 to 70.7)   40.1 (28.3 to 51.9)   N/A

   BRAF mutant                      18 (14.1 to 21.9)       60.7 (53.8 to 67.6)   42.0 (34.2 to 49.8)   27.3 (18.1 to 36.5)

  LDH level                                                                                             

   Normal                           21 (15.1 to 26.9)       69.3 (61.6 to 76.7)   45.9 (36.3 to 55.5)   32.6 (20.4 to 44.6)

   Elevated                         19 (12.8 to 25.1)       58.4 (48.8 to 68.0)   40.1 (29.1 to 51.1)   32.9 (19.9 to 45.8)

   2×\>ULN                          7 (6.1 to 7.9)          32.1 (17.6 to 46.6)   22.9 (8.0 to 37.8)    8.6 (5.5 to 22.7)

  S100B level                                                                                           

   Normal                           22 (18.2 to 25.8)       78.4 (68.6 to 88.2)   44.7 (30.8 to 58.6)   36.1 (20.6 to 51.6)

   Elevated                         17 (9.6 to 24.4)        57.0 (48.2 to 65.8)   42.8 (32.8 to 52.8)   32.3 (20.5 to 44.6)

   10×\>ULN                         17 (8.2 to 25.8)        53.5 (40.4 to 66.6)   30.9 (15.8 to 45.9)   20.6 (1.2 to 40.0)

  Best intracerebral response                                                                           

   CR                               Not reached             92.7 (82.9 to 100)    85.6 (69.3 to 100)    N/A

   PR                               42 (22.6 to 61.4)       86.9 (76.9 to 96.9)   62.9 (46.0 to 79.8)   55.1 (34.5 to 75.7)

   SD                               Not reached             93.6 (86.5 to 100)    83.6 (71.1 to 96.1)   50.2 (19.0 to 81.4)

   PD                               10 (16.7 to 23.3)       39.0 (31.4 to 46.6)   20.0 (13.1 to 26.9)   12.8 (6.0 to 19.3)

  CombiIT                                                                                               

   First line                       17 (10.7 to 23.9)       56.4 (48.9 to 63.8)   44.7 (35.9 to 53.5)   27.9 (11.2 to 44.6)

   Not first line                   21 (17.8 to 24.2)       67.9 (59.9 to 75.9)   41.9 (32.7 to 51.1)   31.6 (21.8 to 41.4)

  BRAF mutant patients                                                                                   

   First-line targeted therapy      22 (17.2 to 26.77)      65.6 (55.2 to 76)     44.3 (34.5 to 57.7)   32.0 (20 to 44)

   First-line CombiIT               16 (7 to 25)            53.6 (43.2 to 64)     42.9 (30.7 to 55.1)   N/A

  BRAF wild-type patients                                                                                

   First-line CombiIT               21 (10.2 to 31.8)       59.6 (52.6 to 73.4)   47 (33.8 to 60.1)     47 (33.8 to 60.1)

   First-line not CombiIT           19 (16.3 to 21.7)       68.3 (50.1 to 74.2)   31.9 (11.5 to 52.3)   31.9 (11.5 to 52.3)

  STR/surgery (at any time point)                                                                       

   Yes                              24 (19.6 to 28.4)       70.6 (63.7 to 77.5)   49.5 (40.9 to 58.1)   36.5 (26.3 to 46.7)

   No                               16 (7.6 to 24.4)        53.2 (41.0 to 65.4)   40.9 (26.6 to 55.2)   N/A

  WBRT                              8 (4.9 to 11.0)         40.7 (28.4 to 53.0)   20.8 (9.4 to 32.2)    10.4 (1.4 to 22.2)

  STR/surgery                                                                                           

   Upfront                          26 (21.1 to 30.9)       72.5 (65.1 to 79.9)   50.9 (41.3 to 60.5)   39.5 (28.3 to 50.7)

   Later                            16 (10.8 to 21.2)       63.7 (47.6 to 79.8)   44.3 (24.9 to 63.7)   22.2 (1.5 to 45.9)

  ECOG-PS                                                                                               

   0                                22 (16.4 to 27.6)       65.7 (59.0 to 72.4)   47.1 (39.1 to 55.1)   36.4 (26.4 to 46.4)

   1                                18 (7.3 to 28.7)        52.3 (40.1 to 64.5)   38.0 (34.1 to 519)    22.2 (6.1 to 38.3)

   \>1                              8 (7.3 to 17.1)         49.3 (31.8 to 66.7)   23.5 (5.5 to 41.5)    5.9 (5.1 to 16.9)

  Presence of symptomatic MBM                                                                            

   No                               19 (10.7 to 27.2)       62.5 (53.4 to 71.8)   45.4 (34.6 to 56.2)   35.1 (21.8 to 48.4)

   Yes                              12 (7.0 to 17.0)        46 (32.1 to 59.9)     28.1 (13.8 to 42.4)   15.0 (0 to 30.7)
  ---------------------------------------------------------------------------------------------------------------------------

CombiIT, nivolumab plus ipilimumab; CR, complete response; ECOG-PS, Eastern Cooperative Oncology Group performance status; MBM, melanoma brain metastases; mOS, median overall survival; PD, progressive disease; PR, partial response; SD, stable disease; STR, stereotactic radiosurgery; ULN, upper level normal; WBRT, whole brain radiotherapy.

[Figure 1B--E](#F1){ref-type="fig"} show the Kaplan-Meier OS curves considering BRAF mutation status, serum LDH level, number of MBM, protein S100B level, and [online supplementary figure S2A--D](#SP1){ref-type="supplementary-material"} show the Kaplan-Meier OS curves according to age groups, sex, ECOG-PS and presence of symptomatic MBM. The results shown are in line with what has been previously described in the univariate Cox regression analysis ([table 2](#T2){ref-type="table"}), that is, there is a statistically significant difference between the groups analyzed regarding serum LDH level (p\<0.0001), number of MBM (p=0.001) and ECOG-PS (p\<0.0001).

Stratifying for the best intracranial response ([figure 1F](#F1){ref-type="fig"}), best OS was observed in patients with complete response (CR) and the difference between the subgroups with CR, partial response (PR), stable disease (SD) and progressive disease (PD) was statistically significant (p\<0.0001). The mOS for patients with an intracranial CR or SD was not reached and for patients with PR and PD was 42 and 10 months, respectively ([table 3](#T3){ref-type="table"}; 95% CI: 22.6 to 61.4; 16.7 to 23.3, respectively). Patients achieving an intracranial CR had an improved 1-year OS rate of 92.7% compared with those with PD with a 1-year OS rate of only 39% (95% CI: 82.9 to 100; 31.4 to 46.6, respectively). Patients with SD showed favorable OS that was better than those with PR at 2 years and similar to PR at 3 years. The subgroups of patients with PR and SD did not differ significantly regarding serum LDH level, protein S100B, number of MBM, ECOG-PS or presence of extracerebral metastases.

Local therapy (STR/surgery) also improved OS ([table 3](#T3){ref-type="table"}, [figure 2A](#F2){ref-type="fig"}): patients who received local therapy (at any time point of the course of the disease) reached a mOS of 24 months compared with patients without local therapy with only 16 months (p=0.009; 95% CI: 19.6 to 28.4 and 7.6 to 24.4, respectively). There was no significant difference in terms of patients' characteristics in these two groups, except for S100B level and presence of symptomatic MBM ([online supplementary table S1](#SP1){ref-type="supplementary-material"}). However, we need to acknowledge that information regarding the presence of symptomatic MBM was missing in approximately 50% of the patients.

![Kaplan-Meier curves for overall survival (OS) according to the following factors: (A) local therapy (STR/surgery, stereotactic radiosurgery or surgery); (B) time of local therapy (before or after combined immunotherapy with nivolumab+ipilimumab); (C) for patients receiving whole brain radiotherapy (WBRT); (D) combined immunotherapy for melanoma brain metastasis (MBM) in first line or later; (E) first-line therapy in patients harboring a BRAF mutation and (F) combined immunotherapy first line or later in BRAF wild-type patients. Patients treated with WBRT were excluded from the analysis in [figure 2A](#F2){ref-type="fig"}. Ten patients (4.5%) from the STR/surgery group (n=220) received only surgery. In the Kaplan-Meier analysis in [figure 2B](#F2){ref-type="fig"}, four patients receiving STR/surgery before combined immunotherapy and two patients receiving STR/surgery after combined immunotherapy were treated with the two techniques in an interval of 2 weeks.](jitc-2019-000333f02){#F2}

When analyzing the time point of local therapy (ie, before or after NIVO+IPI), we found no significant difference in terms of patients' characteristics ([online supplementary table S2](#SP1){ref-type="supplementary-material"}) and the mOS was similar in the two subgroups ([figure 2B](#F2){ref-type="fig"}; p=0.110). However, there seems to be a trend for a benefit of STR/surgery upfront (mOS=26 months vs 16 months; 95% CI: 21.1 to 30.9; 10.8 to 21.2, respectively). Patients who received WBRT had a mOS of 8 months ([table 3](#T3){ref-type="table"}, [figure 2C](#F2){ref-type="fig"}; 95% CI: 4.9 to 11.0) and were analyzed separately.

No OS difference was observed for patients receiving first-line NIVO+IPI compared with those that received combined immunotherapy later ([figure 2D](#F2){ref-type="fig"}; p=0.119). When looking at the patients' characteristics from these two groups, there was a significant difference between them regarding age, BRAFV600 mutation status, number of MBM and treatment with local therapy (STR/surgery) at the time of starting NIVO+IPI ([table 1](#T1){ref-type="table"}). These differences might contribute for similar OS outcomes regardless of therapy line.

In the subgroup of patients with BRAFV600 mutation (242 patients), 83 received first-line treatment with BRAF/MEK inhibitors, 138 received first-line NIVO+IPI and all received combined immunotherapy for MBM in the course of the disease. There was no OS difference when comparing first-line targeted therapy with first-line combined immunotherapy ([figure 2E](#F2){ref-type="fig"}; p=0.085). The line of treatment for combined immunotherapy (first-line or not first-line) had no effect on survival outcome in patients with BRAF wild-type melanoma ([figure 2F](#F2){ref-type="fig"}; p=0.996).

Regarding presence of symptomatic MBM, information was available for only 193 patients ([online supplementary figure S2D](#SP1){ref-type="supplementary-material"}), but there is a trend benefiting patients with asymptomatic MBM (p=0.065). However, if we consider only the patients that received first-line NIVO+IPI for MBM (n=137), the difference in OS between symptomatic and asymptomatic MBM is not significant (p=0.084; data not shown).

Safety {#s3-3}
------

In the present cohort, a total of 236 (62%) patients were reported to have at least one immune-related adverse events (irAEs). In 142 (37%) patients, no irAEs were documented and there was no available information in 2 (1%) patients.

We found no difference (Pearson's χ^2^ test) in terms of onset of irAEs in patients with 1--3 MBM compared with patients with \>3 MBM (p=0.069). Regarding the onset of irAEs in patients who received STR/surgery versus those who did not receive STR/surgery, there was also no significant difference between the two groups (p=0.657). Finally, when analyzing the relation between receiving STR/surgery or not, and the interruption of therapy due to irAEs, we again found no significant difference between the two groups (p=0.913).

Discussion {#s4}
==========

The present study shows that combined immunotherapy with NIVO+IPI can result in improved survival of patients with MBM, comparable to results in other stage IV patients. This is particularly true if intracranial CR, PR or SD has been achieved. The type of intracranial response is a strong predictor for OS. In our cohort, the 2-year OS rates of patients with SD, PR and CR ranged from 63% to 86%, whereas patients with PD had a 2-year OS rate of only 20% ([table 3](#T3){ref-type="table"}). Similar favorable results have been reported in the ABC trial, a randomized phase II study of nivolumab or NIVO+IPI in patients with MBM.[@R16] The 3-year intracranial PFS was above 90% for patients with asymptomatic, treatment-naïve MBM achieving an intracranial CR, and above 50% for patients with PR. We have no explanation why in our cohort patients with SD did better than patients with PR.

In our study, the 1-year and 2-year OS rate were 69% and 41%, respectively, in line with previous reports.[@R9] In the already mentioned ABC trial, patients who received combined immunotherapy had a 1-year and 2-year OS rate of 63%[@R16] and in the Checkmate-204 trial the reported 1-year OS rate was even higher (81.5%).[@R10] The survival rates in these trials are higher than those reported in our cohort. Compared with the ABC trial and the Checkmate-204 trial, which included patients with asymptomatic MBM and treatment-naïve BRAF wild-type patients, 31% (60/193) of the patients in our trial had symptomatic MBM and 20% of the BRAF wild-type patients were pretreated. In the Checkmate-204 trial, 17% of the patients had received previous systemic therapy for MBM and 52% had only one MBM compared with 34% pretreated patients and 53% patients with more than three MBM in our cohort.

Two studies evaluating pembrolizumab in patients with MBM also reported similar outcomes.[@R17] The first study evaluated treatment with pembrolizumab monotherapy in 23 patients with one or more asymptomatic and untreated MBM. With a longer follow-up of 38 months, the mOS time was 17 months (95% CI: 10 months to not reached) and the 2-year OS was 48%. These are in line with our results for patients who did not receive STR/surgery for whom the mOS was 16 months (95% CI: 7.6 to 24.4) and the 2-year OS rate was 41%. However, in this trial, only asymptomatic patients were included and 87% had \<3 MBM, a population with potentially better outcome that the one included in our report. In the second study, Anderson *et al* reported the results of the combination from pembrolizumab and radiation therapy in 21 patients with MBM. Despite the low number of patients included, the percentage of lesions that had a CR (\>30%), was higher than previously reported with systemic therapy or STR alone.

The combination of immunotherapy and local therapy with stereotactic irradiation or surgery improved patients' survival compared with patients who only received NIVO+IPI. This benefit might be related to a synergic effect between radiotherapy and immunotherapy that has been demonstrated both in preclinical and clinical studies.[@R19] The combination of radiation and immune checkpoint inhibitors seems to be effective both in the irradiated and non-irradiated lesions, and this effect might be associated with the activation of cytotoxic T-cells and reduction of myeloid-derived suppressor cells.[@R18]

The benefit of combining local and systemic therapy in MBM has been previously shown by our group and others, with mOS that range from 14 to 25 months and 1-year OS rates between 58% and 78% in the groups that received local and systemic therapy, clearly superior to the outcomes of patients receiving only systemic therapy (mOS between 6 and 13 months and 1-year OS rates ranging from 34% to 53%).[@R14]

In our study, the time point at which the patients received local therapy did not seem to play a significant role in OS: local therapy performed upfront or after initiation of NIVO+IPI resulted in similar OS rates, with a trend benefiting local therapy upfront (mOS 26 months vs 16 months). Different retrospective studies have also addressed this question, and, similar to our cohort, upfront local therapy seems to have better outcomes (mOS of 11--23 months in the group receiving local therapy upfront and 3--9 months in patients receiving local therapy after systemic therapy).[@R34]

There is still an ongoing debate whether some patients might be better served with systemic therapy alone, as we see very positive outcomes.[@R9] Not applying local therapy reduces local complications, potential cognitive impairment and might be particularly adequate for patients with a low number of asymptomatic MBM. This question along with the best sequence regarding local therapy is being addressed in ongoing clinical trials, and in the future, we might be better equipped to decide which patients to treat with the different modalities.[@R37]

In this study, there was a high proportion of patients with BRAFV600-mutated melanoma (63%), but similar to other publications where this subgroup represents between 52% and 65% of the patients.[@R14] Previously, it has been postulated that even in patients with BRAFV600-mutated MBM, first-line systemic treatment should consist of combined immunotherapy. Our analysis showed that there was no difference in OS of patients receiving first-line NIVO+IPI or first-line targeted therapy followed by combined immunotherapy (p=0.085). The two subgroups did not differ significantly ([online supplementary table S4](#SP1){ref-type="supplementary-material"}), except for the number of MBM, where a higher proportion of patients with \>3 MBM received first-line targeted therapy (p=0.002). Our results in this subgroup need to be interpreted with caution since we have not included patients with BRAFV600 mutation who only received targeted therapy.

In the multivariate Cox regression analysis, we identified LDH, S-100B, ECOG-PS and number of MBM as independent prognostic factors. These prognostic factors have already been described in previous analyses,[@R8] but to the best of our knowledge, S100B has only been described as independent prognostic factor for checkpoint inhibitor immunotherapy in one monocentric study.[@R42] It is interesting, however, that both tumor markers, LDH and S100B, remained independent prognostic factors in the multivariate analysis, suggesting that these non-invasive and easy to determine blood parameters can and should be used early in the course of the disease to inform about patients' prognosis.

Regarding the presence of symptomatic MBM, there was no OS differences between patients with and without symptoms (p=0.065), but a trend can be seem showing that patients with symptomatic MBM have worse prognosis that those who are asymptomatic (1-year OS rate 46% and 63%, respectively). In other prospective studies investigating similar cohorts, the OS rate ranged from 66% at 6 months[@R43] to 31% at 12 months.[@R16] Unfortunately, information regarding the presence of symptomatic MBM is missing in approximately 50% of the patients in our study, and therefore, definitive conclusions cannot be drawn from our data.

Strengths of this investigation are that data from 23 German-certified skin cancer centers with high standards for data quality were included. Three-hundred and eighty patients were analyzed which is thus far the largest published cohort of patients with MBM managed in a routine clinical setting. This high number of patients allowed us to perform subgroup analyses, with results of reasonable sensitivity. Furthermore, this study provides long-term follow-up data of patients with MBM covering a period of up to 18 months.

The study limitations are related to its retrospective design. Patients were included regardless of previous systemic and local therapies prior to the combined immunotherapy and thus some heterogeneity of the study population might have contributed to differences in survival outcomes observed in our cohort. The decision to offer local therapy or not was probably influenced by the number and size of MBM. Additionally, the maximum number of MBM considered to be treated individually by STR/surgery might vary between different centers. We have not evaluated intracranial toxicities. However, this aspect might have been considered when planning local therapy and targeted therapy in patients with BRAFV600-mutated melanoma, influencing the systemic therapy offered as well as the therapy sequence in this subgroup.

In conclusion, our study shows that treatment with NIVO+IPI, particularly in combination with STR/surgery improves survival of patients with MBM. Results presented herein also suggest that local therapy with STR/surgery either before or after starting combined immunotherapy might be advantageous to prolonging OS.
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